Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Neovacs    ALNEV   FR0004032746

NEOVACS (ALNEV)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
04/24/2017 04/25/2017 04/26/2017 04/27/2017 04/28/2017 Date
0.82(c) 0.82(c) 0.83(c) 0.84(c) 0.83(c) Last
246 936 199 131 71 129 240 400 126 360 Volume
+1.23% 0.00% +1.22% +1.20% -1.19% Change
More quotes
Financials (€)
Sales 2017 5,51 M
EBIT 2017 -10,8 M
Net income 2017 -11,1 M
Debt 2017 10,0 M
Yield 2017 -
Sales 2018 7,33 M
EBIT 2018 -9,37 M
Net income 2018 -10,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 8,30x
Capi. / Sales2018 4,86x
Capitalization 35,7 M
More Financials
Company
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory and cancerous diseases.It focuses on the development of Tumor Necrosis Factor-Kinoid for treating Crohn's disease and rheumatoid polyarthritis and... 
More about the company
Surperformance© ratings of Neovacs
Trading Rating : Investor Rating : -
More Ratings
Latest news on NEOVACS
03/30 NEOVACS : provides corporate update and reports full year 2016 financial results
03/23 ORIGINAL-RESEARCH : Neovacs S.A. (von GBC AG): BUY
03/13NEOVACS SA : annual earnings release
03/10 NEOVACS : to present IFNalpha Kinoid technology and its clinical outlooks at upc..
03/09 Neovacs to Present IFNα Kinoid Technology and Its Clinical Outlooks at ..
03/09 NEOVACS : to present IFNalpha Kinoid technology and its clinical outlooks at upc..
02/22 NEOVACS : and BioSense Sign Option Agreement Worth Up to 65 Million Plus Royalti..
02/21 NEOVACS : AND BIOSENSE SIGN OPTION AGREEMENT WORTH UP TO €65 MILLION PLUS ROYALT..
02/21 NEOVACS : AND BIOSENSE SIGN OPTION AGREEMENT WORTH UP TO €65 MILLION PLUS ROYALT..
02/16 NEOVACS : Stellar Biotechnologies Congratulates Partner's Decision to Extend Dru..
More news
Sector news : Biotechnology & Medical Research - NEC
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
03/30Neovacs : provides corporate update and reports full year 2016 financial resu.. 
03/23Original-Research: Neovacs S.A. (von GBC AG): BUY  
03/09Neovacs to Present IFNα Kinoid Technology and Its Clinical Outlooks.. 
03/09Neovacs : to present IFNalpha Kinoid technology and its clinical outlooks at .. 
02/26#EquityResearch Week In Review: BioSense Signs $68 Million China Deal With Ne.. 
More tweets
Qtime:10
Advertisement
Chart NEOVACS
Duration : Period :
Neovacs Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Full-screen chart
Technical analysis trends NEOVACS
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 2,37 €
Spread / Average Target 186%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miguel Sieler Chief Executive Officer & Director
Jean-Jacques Bertrand Chairman
Baptiste Pourtout Head-Finance
Géraldine Grouard-Vogel Chief Scientific Officer
Thérèse Croughs Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NEOVACS2.47%39
INCYTE CORPORATION23.95%25 426
QUINTILES IMS HOLDINGS..10.82%19 884
LONZA GROUP AG6.92%11 836
SEATTLE GENETICS, INC.29.43%9 741
CELLTRION, INC.--.--%9 653
More Results